The investment bank upgraded the pharmaceutical name to buy from neutral.
Get this delivered to your inbox, and more info about our products and services.
The investment bank upgraded the pharma stock to overweight from equal weight.
UBS analyst Kevin Caliendo's revised price target implies 15% upside ahead for shares of the health care benefit and pharmacy…
Frank Cappelleri of CappThesis breaks down the bullish technical backdrop for this pharma-related stock.
This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround.
We are making a pharmaceutical position swap into Wednesday's relief rally.
The stock is one of seven out-of-favor names Jim Cramer highlighted at our recent Monthly Meeting.
